DBV Technologies Announces the Filing of its 2026 Half-Year Report ― Conditions for Accessing or Consulting the Report

DBV Technologies (Nasdaq: DBVT) announced that it has filed its 2026 Half-Year Report for the semester ended June 30, 2026 with the French market authority, Autorité des Marchés Financiers (AMF).

Rhea-AI Summary

DBV Technologies (Nasdaq: DBVT) announced that it has filed its 2026 Half-Year Report for the semester ended June 30, 2026 with the French market authority, Autorité des Marchés Financiers (AMF). According to the company, the report is available in French on its website under Investors/Financial Information and on the AMF website.

Argus Jul 17 session 4 alerts

-1.08% close to close 1.4x rel. volume Open Argus

Details

News Market Reaction – DBVT

$942.25M Market Cap

In the Jul 17 session, DBVT declined 1.08%, reflecting a mild negative market reaction. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Historical Context

5 past events · Latest: Jul 06

5 events

1. Jul 06

   Liquidity contract report

   24h Move

   +11.2%

   Reported half-year activity and balances under the ODDO BHF liquidity contract.

2. Jun 29

   BLA submission update

   24h Move

   +2.5%

   Outlined BLA timing for VIASKIN Peanut Patch with no new data requested by FDA.

3. Jun 23

   Index inclusion news

   24h Move

   -3.2%

   Announced inclusion in the Euronext Tech Leaders index for high-growth companies.

4. Jun 09

   Conference participation update

   24h Move

   +0.3%

   Confirmed 1-on-1 meetings at Goldman Sachs healthcare conference; fireside chat cancelled.

5. Jun 08

   Clinical data presentation

   24h Move

   +0.3%

   Planned presentation of positive VITESSE data and THRIVE design at EAACI Congress.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Châtillon, France, July 16, 2026

DBV Technologies Announces the Filing of its 2026 Half-Year Report ― Conditions for Accessing or Consulting the Report

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company (the “Company”), today announced the filing, for the semester ended June 30, 2026, of its Half-Year Report with the French market authority, “Autorité des Marchés Financiers” (“AMF”).

The 2026 Half-Year Report can be consulted or downloaded from the Company’s website (www.dbv-technologies.com) in the section Investors/Financial Information, and on the AMF website (www.amf-france.org), in French only.

About DBV Technologies
DBV Technologies is a late-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV Technologies is currently focused on investigating the use of its proprietary VIASKIN^® patch technology to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT), the VIASKIN^® Peanut Patch is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual’s underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin’s immune tolerizing properties. DBV Technologies is committed to transforming the care of people with food allergies. The Company’s food allergy programs include ongoing clinical trials of VIASKIN^® Peanut Patch in toddlers (1 through 3 years of age) and children (4 through 7 years of age) with peanut allergy.

DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (DBVT – CUSIP: 23306J309).

For more information, please visit www.dbv-technologies.com and engage with us on X (formerly Twitter) and LinkedIn.

VIASKIN is a registered trademark of DBV Technologies.

Investor Contact
Jonathan Neely
DBV Technologies
jonathan.neely@dbv-technologies.com

Media Contact
Brett Whelan
DBV Technologies
brett.whelan@dbv-technologies.com

Attachment

• PDF Version

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did DBV Technologies (DBVT) announce about its 2026 Half-Year Report on July 16, 2026?

DBV Technologies announced it has filed its 2026 Half-Year Report for the semester ended June 30, 2026 with the French market authority AMF. According to the company, this filing formalizes disclosure of its mid-year information to the French market.

Where can investors access DBV Technologies’ 2026 Half-Year Report for DBVT shares?

Investors can access DBV Technologies’ 2026 Half-Year Report on the company’s website in the Investors/Financial Information section. According to the company, the report is also available on the AMF website, providing two official online access points.

In what language is DBV Technologies’ 2026 Half-Year Report (DBVT) available?

DBV Technologies’ 2026 Half-Year Report is available in French only. According to the company, the document can be consulted or downloaded from its website and from the AMF website exclusively in the French language.

Which period does DBV Technologies’ 2026 Half-Year Report for DBVT cover?

DBV Technologies’ 2026 Half-Year Report covers the semester ended June 30, 2026. According to the company, this half-year document relates specifically to the first six months of 2026 for regulatory and investor information purposes.

What is the role of the AMF in DBV Technologies’ 2026 Half-Year Report filing?

The AMF is the French market authority where DBV Technologies filed its 2026 Half-Year Report. According to the company, the report can be consulted on the AMF website, reflecting compliance with French market disclosure requirements.